Abbott Cleared the First Dual Glucose and Ketone Sensor. FDA Judged Accuracy, Not Admissions.
- The FDA authorised Abbott Diabetes Care‘s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System on 25 August 2026 through the De Novo pathway, for people aged 2 and older living with diabetes. It is the first wearable in the US to monitor ketones continuously and the first anywhere to track ketones and glucose in one device.
- The sensor reads both analytes in interstitial fluid every minute, day and night, sending current values and trend direction to a smartphone and firing automatic alerts when ketones reach a concerning threshold. FDA notes that ketone readings should always be interpreted alongside glucose and symptoms.
- The evidence package is six clinical studies enrolling more than 600 participants aged 2 and older, assessing accuracy across a range of ketone and glucose levels. FDA states the device accurately tracked clinically meaningful ketone differences across its 10-day wear period, including identifying elevated ketones before the onset of diabetic ketoacidosis. It held Breakthrough Device designation beforehand.
- CDC figures cited in the authorisation put 40.1 million Americans with diabetes and 2.1 million with type 1. The De Novo establishes special controls covering labelling and performance testing, which now define the category for anyone following.
Access read
The label says diabetes. The clinical argument in the release is about type 1. That gap is where every coverage conversation will start, and it starts from 2.1 million people, not 40.1 million.
- Forecast on 2.1 million. FDA quotes both numbers and makes the DKA case for type 1. A broad label helps at prescription and hurts at coverage review, because a medical director will ask why a type 2 patient on metformin needs continuous ketone data. Have that answer written before the first P&T meeting.
- FDA judged accuracy. Payers will want admissions. Across 6 studies the finding is that the sensor tracks ketone movement accurately and flags elevation before DKA develops. Detection is not prevention, and nobody has yet shown these alerts reduce DKA hospitalisations. That is the endpoint a coverage policy will be written against.
- The wear period sets the cost base, so price the year not the sensor. A 10-day sensor is roughly 36 units per patient per year. Formulary committees will convert to annual cost per patient immediately, and the avoided-admission argument has to clear that number rather than the unit price.
Read the original source (US Food and Drug Administration) →